Notícias Genmin Limited - GEN | Ações Australian Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Genmin Limited (GEN)

0,041

-0,003

(-6,82%)

Fechado 21 Dezembro 2:00AM

Atrasado por 20 minutos

Ferramentas de nível profissional para investidores individuais.

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

Daratumumab Receives Breakthrough Therapy Designation From US Food and Drug Administration

Arzerra First Quarter 2013 Net Sales Figures

Passing of Genmab A/S' Annual General Meeting

Genmab Announces Final US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit

Daratumumab Granted Fast Track Designation From U.S. Food and Drug Administration

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições